This week's must-know community updates, latest research & events
April 02, 2025 • Estimated Reading Time: 1 minute
Latest Research
Microscopic Polyangiitis (MPA) is a rare autoimmune disease affecting small blood vessels. Akao et al. (2025) It often causes kidney inflammation, weight loss, skin lesions, nerve damage, and fevers. MPA is associated with antineutrophil cytoplasmic antibodies (ANCA) and typically treated with corticosteroids and immunosuppressants like cyclophosphamide or rituximab.
Diagnosis involves clinical findings, ANCA tests, and sometimes a biopsy. Treatment focuses on controlling inflammation and preventing organ damage using a combination of medications to manage symptoms and induce remission. This approach is crucial for managing MPA effectively, as highlighted in medical literature (Microscopic Polyangiitis - PMC, 2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: